|
|
|
||||||||||||||
|
|
![]() |
PATIENT CENTRIC APPROACH A patient-centric approach puts the individual in charge of their well-being by defining treatment and operational policies that center around them. This is made possible by advances in technology. |
|
||||||||||||
|
|
|
||||||||||||||
|
|
|||||||||||||||
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
|
|
SWISS DOLORCLAST “The Gold Standard in radial shockwave therapy”, FDA approved |
|
|||||||||||||
![]() |
|
||||||||||||||
|
|
|
||||||||||||||
|
|
|
|
|
|
|||||||||||
| What is ESWT? • Non-invasive procedure • No anaesthetic, medication or surgery • Sound waves stimulate healing for many • Shockwaves trigger a variety of effective |
|
How ESWT works • A shockwave is generated in the handpiece as a • The shockwave is delivered to the tissue • The shockwave radiates out, extending to the entire • Usually no more than 3-4 sessions are needed • Per session : approximately 2000 impulses at 2.5 bars • No anaesthetic required • No surgery or other therapy is required |
|||||||||||||
|
|
|
||||||||||||||
|
|
|
|
|
||||||||||||
|
|
Benefits of Swiss Dolorclast “ESWT offers two main advantages over traditional surgical methods: fewer potential complications and a faster return to normal activity.” FDA |
|
Results |
||||||||||||
| For the Patient • No anaesthesia • Non invasive • No medication • No surgery • No need for other therapy • Fast treatment – 30 minutes • Fewer complications • Virtually painless after treatment • Quick recovery • Quick results • Outpatient treatment – • Lower time and financial cost |
|
For the Practitioner • High patient acceptance • Simple procedure • “Gold standard in ESWT” – • FDA approved • European patent – Dolorclast • Broad range of applications • High return on investment • Low operating costs • Low maintenance • High level product support |
|||||||||||||
|
|
|||||||||||||||
![]() |
![]() |
||||||||||||||
|
|
|||||||||||||||
© Copyright 2007 Spectrum Technology UK Ltd. | Disclaimer | Website design by Tanya Morgan |
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|